Episode 59 - Rethinking Set and Setting: Dr. Roberto Malinow's Revolutionary Hypothesis on How Ketamine Actually Works
Leading neuroscientist Dr. Roberto Malinow challenges conventional ketamine therapy protocols, hypothesizing we should activate negative thoughts and pain during treatment rather than creating traditional peaceful environments.
This week, host Sam Ko goes upstream from our usual clinical and business topics to sit down with Dr. Roberto Malinow, emeritus professor at UC San Diego, member of both the National Academy of Sciences and the National Academy of Medicine, and one of the world's leading researchers on synaptic plasticity and NMDA receptor biology. His work has been cited more than 30,000 times, and his recent perspective piece takes a very different view of what's actually happening during a ketamine infusion.
The core of this conversation is his hypothesis that ketamine works by selectively weakening hyperactive brain circuits, but only the ones actively firing while the drug is on board.
It's a finding that raises some genuinely uncomfortable questions about the standard set and setting approach, and points to chronic pain treatment as a practical place to start testing these ideas clinically.
You'll also hear about the brain's "disappointment center," the lateral habenula, and why it may be hyperactive in depression, the Stanford anesthesia study and what it suggests about brain activity during treatment, and a wide ranging look at consciousness, optogenetics, the gut-brain connection, and what basic science still doesn't fully understand about how psychiatric drugs work.
What You'll Learn in This Episode:
Revolutionary ketamine mechanism - How Dr. Malinow's hypothesis suggests ketamine works by weakening hyperactive brain circuits, but only when those specific circuits are actively firing during treatment
The disappointment center concept - Understanding the lateral habenula as the brain's disappointment center that inhibits dopamine and may be hyperactive in depression, serving an evolutionary purpose in reinforcement learning
Challenge to set and setting orthodoxy - How activating negative thoughts or painful experiences could possibly enhance therapeutic outcomes
Neuroplasticity fundamentals - How synapses can be rapidly modified and why NMDA receptors are crucial for both strengthening and weakening neural pathways, forming the basis for learning and memory
Rapid vs. delayed therapeutic effects - Why ketamine can work almost immediately while traditional antidepressants take weeks, and what this reveals about different mechanisms of action
Chronic pain treatment implications - How activating pain circuits during ketamine infusions might be more effective than current protocols, and why chronic pain could be the ideal testing ground for this hypothesis
Basic science translation - How laboratory findings about synaptic plasticity and NMDA receptors connect to real-world therapeutic applications in depression, PTSD, and pain management
Optogenetics technology - How scientists can now deliver light-sensitive proteins to specific neurons, allowing precise activation or inactivation of brain circuits to study behavior and memory
Memory manipulation research - Fascinating studies showing how specific memories can be turned on and off using targeted brain stimulation, with implications for trauma and addiction treatment
Consciousness and synaptic function - Exploring the complex relationship between individual neurons and higher-order brain functions, and why bridging these levels remains challenging
Key Takeaways:
Ketamine's rapid action requires neural circuit activity - Unlike traditional antidepressants that work globally over weeks, ketamine appears to target specifically active circuits within hours, explaining its revolutionary speed of action
Hyperactive circuits may need activation to be weakened - The counterintuitive finding that problematic brain circuits might need to be firing during ketamine treatment for the drug to effectively reduce their activity long-term
Set and setting assumptions need reexamination - Current practices emphasizing calm, positive environments may be missing therapeutic opportunities by not engaging the circuits that need treatment
Chronic pain offers ideal research opportunity - Because pain circuits can be more easily and reliably activated than specific thought patterns, chronic pain conditions may provide the best initial testing ground for this hypothesis
Depression involves circuit-level dysfunction - Negative thoughts, ruminations, and feelings of worthlessness may reflect hyperactive brain circuits that could be specifically targeted during treatment
NMDA receptors are central to plasticity - These receptors mediate both the strengthening and weakening of synaptic connections, making them crucial for learning, memory, and therapeutic change
Surgical ketamine studies support activity requirement - Research showing that ketamine doesn't improve depression in unconscious surgical patients supports the idea that brain activity is necessary for therapeutic effects
Research needs careful experimental design - Testing this hypothesis will require precisely controlled studies that can activate target circuits during ketamine administration while measuring outcomes
Listen to the episode on Apple Podcasts, Spotify, Overcast, or on your favorite podcast platform. Watch the discussion on YouTube here.
Episode 59 show notes:
00:00:00 - Teaser: Those hyperactive circuits…
00:00:24 Episode Introduction and Guest Overview
00:01:12 Sam Introduces and Welcomes Dr. Roberto Malinow
00:02:41 Background: From Reed College to The MD/PhD Path
00:05:17 Why Basic Science Won Out Over Clinical Medicine
00:06:06 The Lecture That Started It All: Professor Rodolfo Llinás and Synapses
00:06:51 How Ketamine Interacts with the NMDA Receptor
00:07:47 The "Disappointment Center": What the Lateral Habenula Does and Why It Matters in Depression
00:09:16 The Standard Set and Setting Approach in Outpatient Ketamine Clinics
00:10:12 The Three-Part Hypothesis: Neuroplasticity, Hyperactive Circuits, and Negative Thoughts
00:11:49 Written Exposure Therapy and PTSD: Priming Circuits Before the Infusion
00:12:53 Chronic Pain as the Easier Testing Ground for the Hypothesis
00:14:20 Activating the Pain Pathways During a Ketamine Infusion
00:17:23 The Anesthesia Study (Heifets/Stanford): Why the Brain Needs to Be Active
00:18:48 What Would a Human Study Design Actually Look Like?
00:20:41 Animal Study Evidence Supporting the Active-Stimulus Hypothesis
00:21:33 Zooming Out: Synapses, Consciousness, and the Shakespeare Analogy
00:23:18 Optogenetics Explained: Using Light to Control Specific Neurons
00:27:31 What Don't We Understand About Depression?
00:28:29 Lateral Habenula in Animal Depression Models and Dr. Malinow's Own Experiments
00:29:13 The Dystopian Scenario: Using Ketamine-Like Drugs to Wipe Out Ideas
00:31:31 Common Misconceptions Clinicians Have About Synapses
00:32:47 What Surprised Dr. Malinow Most About Studying Synapses
00:35:15 Why Ketamine Works Rapidly While SSRIs Take Weeks
00:37:30 The "Party Trick": Learning Is Neuroplasticity in Real Time
00:39:13 NMDA Receptors and Their Role in Learning and Memory
00:39:47 Optogenetics Research: Turning Fear Memories On and Off in Animals
00:42:08 Glutamate: 90% of Synaptic Transmission Explained
00:43:55 Synapses in the Gut: The Enteric Nervous System
00:45:58 The Gut-Brain Connection and Future Research
00:46:23 Papers Worth Reading in the Ketamine Space
00:47:50 The Psychedelic Renaissance: Psilocybin, the Disappointment Center, and What's Next
00:50:20 Could the Activation Hypothesis Apply to Psilocybin and MDMA as Well?
00:52:57 Rapid-Fire Questions Begin
00:53:19 Time Travel
00:54:19 Hidden Talent
00:54:48 Alternate Career
00:55:42 Advice to 18-Year-Old Roberto
00:56:29 Final Thoughts and Call to Action for Clinicians
00:57:00 Where to Find Dr. Malinow's Research (UCSD Website)
00:57:40 Sam's Closing Remarks
00:58:32 Episode Ending
Thanks for Listening
Professional Education Disclaimer: This content is intended exclusively for licensed healthcare professionals and should not be used by patients for self-treatment or self-education. The information presented reflects individual provider experiences and should not replace clinical judgment, professional training, or comprehensive research. Healthcare providers must conduct their own due diligence, consult current literature, and evaluate treatment approaches within their specific practice context and regulatory environment. This educational content does not constitute medical advice for specific patients or clinical situations - treatment decisions should always be based on individual patient assessment and adherence to professional medical standards.
Frequently Asked Questions
What is the lateral habenula and why might it play a role in depression?
The lateral habenula is a small region of the brain located next to the thalamus, sometimes referred to as the "disappointment center." It works by inhibiting dopamine centers, which is thought to be the mechanism behind feelings of disappointment and negative reinforcement. In depressed patients, this area may become hyperactive, meaning it fires too easily or too frequently, potentially contributing to the persistent negative thoughts, guilt, and ruminations that are difficult for depressed patients to turn off. Research in animal models of depression has found the lateral habenula to be hyperactive, and experiments inactivating this region have been associated with reduced depressive symptoms.
Why does ketamine appear to work so much faster than traditional antidepressants?
Standard antidepressants like SSRIs typically take several weeks to produce therapeutic effects. Ketamine, by contrast, can begin reducing depression symptoms almost immediately, including acute suicidality. One hypothesis is that ketamine works by rapidly weakening hyperactive synaptic circuits through a neuroplasticity mechanism rather than the slower neurotransmitter modulation relied upon by traditional antidepressants. This rapid circuit-level effect may explain why ketamine has been considered a significant development in psychiatry, particularly for patients who cannot safely wait weeks for treatment to take effect.
Could activating negative thoughts during a ketamine infusion improve therapeutic outcomes?
Dr. Roberto Malinow's hypothesis suggests that ketamine may selectively weaken whichever brain circuits are actively firing while the drug is on board. If the circuits underlying negative thoughts, guilt, or ruminations are active during the infusion, those specific hyperactive pathways may be more likely to be weakened, potentially reducing depressive symptoms. This stands in contrast to the current standard set and setting approach, which typically aims to create a calm, positive environment before and during treatment. Priming patients through written exercises that activate depressive thought patterns before the infusion could be one way to test this idea, though this remains a hypothesis requiring clinical research to validate.
How might ketamine providers approach chronic pain treatment differently based on this research?
For chronic pain conditions thought to involve central sensitization of pain pathways in the spinal cord or brain, Dr. Malinow's hypothesis suggests that activating the painful stimulus while ketamine is on board could be more effective than treating in a neutral or relaxed state. Basic science experiments in animals have shown that drugs similar to ketamine only reduced pain when the painful stimulus was being delivered during drug administration. For providers, this could mean identifying and selectively activating the specific pain source during infusion, as long as the underlying inflammatory or physiological cause has already resolved. Chronic pain may be a more practical testing ground for this hypothesis than depression because the stimulus is more reliably accessible.
What does the Stanford anesthesia study suggest about how ketamine works in depression treatment?
Research associated with Dr. Boris Heifets at Stanford examined depressed patients who received ketamine while under general anesthesia and found that ketamine did not improve depression symptoms under those conditions. This finding is consistent with the hypothesis that the brain needs to be in an active state for ketamine to produce its antidepressant effects. Both the ketamine and non-ketamine groups showed reductions in depression scores, which some attribute to the surgical experience itself, though the lack of additional benefit from ketamine in unconscious patients supports the idea that circuit activation during treatment may be an important factor in therapeutic outcomes.
What is optogenetics and how is it being used to study memory and depression?
Optogenetics is a research technique that uses a virus to deliver genes for light-sensitive proteins into specific neurons. Once those neurons express the protein, they can be selectively activated or deactivated by shining light on them, allowing researchers to ask precise questions about which brain pathways underlie which behaviors. Dr. Malinow's lab used this technique to implant, erase, and restore specific fear memories in animals by targeting pathways into the amygdala and modifying synaptic strength via long-term potentiation (LTP) and long-term depression (LTD). This work demonstrates that memories can be selectively weakened and reinstated using knowledge of synaptic plasticity mechanisms, many of which depend on NMDA receptor function. While optogenetics is currently a basic science tool rather than a clinical one, it is providing foundational insights into how circuits underlying depression and chronic pain might be targeted therapeutically in the future.
Connect with Dr. Malinow
Selected Links From the Episode: